| [1] |
Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness [J]. Crit Care Clin, 2006, 22(2): 255-271.
|
| [2] |
Susla GM. The impact of continuous renal replacement therapy on drug therapy [J]. Clin Pharmacol Ther, 2009, 86(5): 562-565.
|
| [3] |
Vaara S, Pettila V, Kaukonen KM. Quality of pharmacokinetic studies in critically ill patients receiving continuous renal replacement therapy [J]. Acta Anaesthesiol Scand, 2012, 56(2): 147-157.
|
| [4] |
Nolin TD, Aronoff GR, Fissell WH, et al. Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative [J]. Clin J Am Soc Nephrol, 2015, 10(1): 159-164.
|
| [5] |
Schetz M. Drug dosing in continuous renal replacement therapy: general rules [J]. Curt Opin Crit Care, 2007, 13(6): 645-651.
|
| [6] |
Teraoka S, Mineshima M, Hoshino T, et al. Can cytokines be removed by hemofiltration or hemoadsorption [J]? ASAIO J, 2000, 46(4): 448-451.
|
| [7] |
Mitzner S, Klammt S, Stange J,et al. Albumin regeneration in liver support-comparison of different methods [J]. Ther Apher Dial, 2006, 10(2): 108-117.
|
| [8] |
Yogaratnam D, Ditch K, Medeiros K, et al. The Impact of Liver and Renal Dysfunction on the Pharmacokinetics and Pharmacodynamics of Sedative and Analgesic Drugs in Critically Ⅲ Adult Patients [J]. Crit Care Nurs Clin North Am, 2016, 28(2): 183-194.
|
| [9] |
Gepts E, Camu F, Cockshott ID, et al. Disposition of propofol administered as constant rate intravenous infusions in humans [J]. Anesth Analg, 1987, 66(12): 1256-1263.
|
| [10] |
Dawidowicz AL, Kalitynski R, Kobielski M, et al. Influence of propofol concentration in human plasma on free fraction of the drug [J]. Chem Biol Interact, 2006, 159(2): 149-155.
|
| [11] |
Takizawa D, Sato E, Hiraoka H, et al. Changes in apparent systemic clearance of propofol during transplantation of living related donor liver [J]. Br J Anaeth, 2005, 95(5): 643-647.
|
| [12] |
Dawidowicz AL, Fornal E, Mardarowicz M, et al. The role of human lungs in biotransformation of propofol [J]. Anesthesiology, 2000, 93(4): 992-997.
|
| [13] |
Shafer A, Doze VA, Shafer SL, et al. Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia [J]. Anesthesiology, 1988, 69(3): 348-356.
|
| [14] |
Schüttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study [J]. Anesthesiology, 2000, 92(3): 727-738.
|
| [15] |
Kataria BK, Ved SA, Nicodemus HF, et al. The pharmacokinetics of propofol in children using three different data analysis approaches [J]. Anesthesiology, 1994, 80(1): 104-122.
|
| [16] |
Johnson KB, Egan TD, Kern SE, et al. The influence of hemorrhagic shock on propofol: a pharmacokinetic and pharmacodynamic analysis [J]. Anesthesiology, 2003, 99(2): 409-420.
|
| [17] |
Amrein R, Hetzel W. Pharmacology of Dormicum (midazolam) and Anexate (flumazenil) [J]. Acta Anaesthesiol Scand Suppl, 1990, 92: 6-15.
|
| [18] |
Panzer O, Moitra V, Sladen RN. Pharmacology of sedative-analgesic agents: dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role of peripheral Mu antagonists [J]. Anesthesiol Clin, 2011, 29(4): 587-605.
|
| [19] |
Vincent JL, Shehabi Y, Walsh TS, et al. Comfort and patient-centred care without excessive sedation: the eCASH concept [J]. Intensive Care Med, 2016, 42(6): 962-971.
|
| [20] |
Yapici N, Coruh T, Kehlibar T, et al. Dexmedetomidine in cardiac surgery patients who fail extubation and present with a delirium state [J]. Heart Surg Forum, 2011, 14(2): E93- E98.
|
| [21] |
Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit [J]. Crit Care Med, 2013, 41(1): 263-306.
|
| [22] |
Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease [J]. Anaesth Intensive Care, 2005, 33(3): 311-322.
|
| [23] |
Zöllner C, Schäfer M. Opioids in anesthesia [J]. Anaesthesist, 2008, 57(7): 729-740.
|
| [24] |
Fyman PN, ReynoldsJR, MoserF, et al. Pharmacokinetics of sufentanil in patients undergoing renal transplantation [J]. Can J Anaesth, 1988, 35(3(Pt 1)): 312-315.
|
| [25] |
Sztark F, Lagneau F. Agents for sedation and analgesia in the intensive care unit [J]. Ann Fr Anesth Reanim, 2008, 27(7-8): 560-566.
|
| [26] |
Stroumpos C, Manolaraki M, Paspatis GA. Remifentanil, a different opioid: potential clinical applications and safety aspects [J]. Expert Opin Drug Saf, 2010, 9(2): 355-364.
|
| [27] |
Mazoit JX, Butscher K, Samii K. Morphine in postoperative patients: pharmacokinetics and pharmacodynamics of metabolites [J]. AnesthAnalg, 2007, 105(1): 70-78.
|
| [28] |
Power BM, Forbes AM, van Heerden PV, et al. Pharmacokinetics of drugs used in critically ill adults [J]. Clin Pharmacokinet, 1998, 34(1): 25-56.
|
| [29] |
Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction [J] .Eur J ClinPharmacol, 2009, 65(8): 757-773.
|
| [30] |
Yogaratnam D, Miller MA, Smith BS. The effects of liver and renal dysfunction on the pharmacokinetics of sedatives and analgesics in the critically ill patient [J]. Crit Care Nurs Clin North Am, 2005, 17(3): 245-250.
|
| [31] |
Yogaratnam D, Ditch K, Medeiros K, et al. The Impact of Liver and Renal Dysfunction on the Pharmacokinetics and Pharmacodynamics of Sedative and Analgesic Drugs in Critically Ill Adult Patients [J]. Crit Care Nurs Clin North Am, 2016, 28(2): 183-194.
|
| [32] |
Bolon M, Bastien O, Flamens C, et al. Midazolam disposition in patients undergoing continuous venovenous hemodialysis [J]. J Clin Pharmacol, 2001, 41(9): 959-962.
|
| [33] |
Lam SW, Alexander E. Dexmedetomidine use in critical care [J]. AACN Adv Crit Care, 2008, 19(2):113-120.
|
| [34] |
Wagner BK, O′Hara DA. Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients [J]. Clin Pharmacokinet, 1997, 33(6): 426-453.
|
| [35] |
Wilhelm W, Kreuer S. The place for short-acting opioids: special emphasis on remifentanil [J]. Crit Care, 2008, 12(3 Suppl): S5.
|